Taken together, these data suggest that binding between ILK and integrin β3 is impaired in BCR-ABL1T315I+ cells and that ILK plays an important role in progression of BCR-ABL1T315I+ CML, at least partly via modulation of fibronectin levels in the BMM. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.